companies developing glp-1 drugs 2.0: Where the Next Wave of Value Will Be Created Looming GLP-1 drug patent expirations

Description

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinsons disease by increasing expression of BNDF

Had we assessed risk of bias for less objective outcomes, such as participant-reported gastrointestinal adverse events, overall risk of bias for such outcomes in these trials might have been deemed of some concern

only 45.9% of GLP-1 patients JAMA Network Surgery also yielded greater reductions in excess weight

Sensitivity analyses and negative outcome controls We tested the robustness of our results in multiple sensitivity analyses, which yielded results consistent (in direction and magnitude) with those of the primary approach (supplementary table S15)